20+ Years of API Innovation: What We’ve Learned in Respiratory Drug Development

Developing APIs for respiratory medicines requires precise particle control, consistent quality and a thorough understanding of formulation needs. Our API micronization expertise reflects 20 years of API innovation, helping pharmaceutical companies address technical challenges in inhaled drug development. 

Key Milestones in API Innovation 

Over the years, we have seen how advances in particle engineering, analytical methods and process control have improved API manufacturing. These developments have help us meet increasingly demanding formulation requirements and support more consistent product quality. 

Lessons from early inhalation API projects 

Our experience with inhalation projects has shown us how strongly particle properties influence formulation performance. Particle size distribution, morphology and powder behavior can affect dispersion and lung deposition. 

These lessons have reinforced the importance of defining material specifications early and monitoring critical properties throughout manufacturing. 

Advances in Micronization Techniques 

Micronization reduces particle size to meet the requirements of specific pharmaceutical applications. Advances in milling technology and process control allow us to achieve target particle size distributions more consistently. 

However, reducing particle size alone is not enough. We must also control process conditions to protect API quality and achieve the physical properties required for the intended formulation. 

Our API manufacturing experience helps us select suitable process parameters and assess their impact on particle characteristics. 

Maintaining Quality and Compliance Over Time 

We understand that consistent quality requires more than meeting specifications in a single batch. That is why our processes rely on appropriate controls, analytical methods and documentation to demonstrate reproducibility. 

As processes evolve, change control and ongoing monitoring help us ensure that modifications do not compromise established quality attributes. These practices also support compliance with applicable GMP requirements and regulatory expectations. 

Partnering for Successful Respiratory Therapy Development 

Developing respiratory therapy APIs requires close coordination between API manufacturers and pharmaceutical development teams. We work to understand formulation requirements early, helping prevent avoidable technical issues and delays. 

Clear communication also supports decision-making during scale-up. By aligning technical requirements and project objectives, we help our partners progress toward reliable manufacturing processes. 

Inke’s Expertise Driving Ongoing Innovation 

Developing inhalation APIs requires precise control over particle properties and consistent manufacturing processes. At INKE, we use our pharma experience to help pharmaceutical companies meet specific API requirements and prepare processes for larger-scale production. 

Combining experience, technical excellence, and customer focus 

With more than two decades of API micronization expertise, we understand the technical challenges involved in developing and manufacturing complex APIs. So, if you are developing an inhaled medicine and need a reliable manufacturing partner, contact us to discuss your project requirements.